One response to AstraZeneca’s itemizing rejig is aid. The large fear was that the second largest firm on the London Inventory Trade would skip off completely to New York, preserving solely a secondary itemizing within the UK as a face-saver for the federal government. That, thankfully, just isn’t the plan.
Support Greater and Subscribe to view content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
